CAS 2023788-19-2 Tirzepatide good quality favorable price Factory supply hot sales and security customs door to door

    Tirzepatide is a novel dual receptor channel agonist of glucagon-like peptide -1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which is administered once a week. GLP-1 and GIP are both incretin, which are polypeptides secreted by human gastrointestinal mucosa. The former can bind to receptors on islet cells and stimulate insulin secretion, thus reducing blood sugar, delaying gastric emptying and suppressing appetite, thus controlling weight. The latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement GLP-1 receptor agonist. Tirzepatide integrates two insulin-promoting effects into a single molecule, which represents a new type of drug for treating type 2 diabetes.

    Tirzepatide and semaglutide have similar sequences, and the lys side chain in the sequence is modified by PEG, which is the functional group of the polypeptide and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is a dual agonist of glucose-dependent insulin nutritional polypeptide (GIP) and glucagon-like peptide -1(GLP-1) receptor, which is being developed to treat type 2 diabetes mellitus and has entered the clinical stage.